International Journal of Cell Biology movement and traﬃcking in cortical neurons,” Neurobiology of Disease, vol. 22, no. 2, pp. 388–400, 2006. [72] E. Trushina, R. B. Dyer, J. D. Badger et al., “Mutant huntingtin impairs axonal traﬃcking in mammalian neurons in vivo and in vitro,” Molecular and Cellular Biology, vol. 24, no. 18, pp. 8195–8209, 2004. [73] A. Weihofen, K. J. Thomas, B. L. Ostaszewski, M. R. Cookson, and D. J. Selkoe, “Pink1 forms a multiprotein complex with miro and milton, linking Pink1 function to mitochondrial traﬃcking,” Biochemistry, vol. 48, no. 9, pp. 2045–2052, 2009. [74] H. J. Lee, F. Khoshaghideh, S. Lee, and S. J. Lee, “Impairment of microtubule-dependent traﬃcking by overexpression of α-synuclein,” European Journal of Neuroscience, vol. 24, no. 11, pp. 3153–3162, 2006. [75] F. Gillardon, “Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability—A point of convergence in Parkinsonian neurodegeneration?” Journal of Neurochemistry, vol. 110, no. 5, pp. 1514–1522, 2009. [76] F. Yang, Q. Jiang, J. Zhao, Y. Ren, M. D. Sutton, and J. Feng, “Parkin stabilizes microtubules through strong binding mediated by three independent domains,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 17154–17162, 2005. [77] K. J. Kopeikina, G. A. Carlson, R. Pitstick et al., “Tau accumulation causes mitochondrial distribution deﬁcits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain,” American Journal of Pathology, vol. 179, no. 4, pp. 2071–2082, 2011. [78] C. X. Gong and K. Iqbal, “Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease,” Current Medicinal Chemistry, vol. 15, no. 23, pp. 2321–2328, 2008. [79] X. Qi, M. H. Disatnik, N. Shen, R. A. Sobel, and D. Mochly- Rosen, “Aberrant mitochondrial ﬁssion in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo,” Molecular Biology of the Cell, vol. 22, no. 2, pp. 256–265, 2011. [80] S. J. Tabrizi, M. W. J. Cleeter, J. Xuereb, J.-W. Taanman, J. M. Cooper, and A. H. V. Schapira, “Biochemical abnormalities and excitotoxicity in Huntington’s disease brain,” Annals of Neurology, vol. 45, no. 1, pp. 25–32, 1999. [81] E. Brouillet, C. Jacquard, N. Bizat, and D. Blum, “3- Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease,” Journal of Neurochemistry, vol. 95, no. 6, pp. 1521–1540, 2005. [82] W. Song, J. Chen, A. Petrilli et al., “Mutant huntingtin binds the mitochondrial ﬁssion GTPase dynamin-related protein-1 and increases its enzymatic activity,” Nature Medicine, vol. 17, no. 3, pp. 377–383, 2011. [83] A. Kathrin Lutz, N. Exner, M. E. Fett et al., “Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation,” The Journal of Biological Chemistry, vol. 284, no. 34, pp. 22938–22951, 2009. [84] A. Sandebring, K. J. Thomas, A. Beilina et al., “Mitochondrial alterations in PINK1 deﬁcient cells are inﬂuenced by calcineurin-dependent dephosphorylation of dynamin- related protein 1,” PLoS ONE, vol. 4, no. 5, Article ID e5701, 2009. [85] R. K. Dagda, A. M. Gusdon, I. Pien et al., “Mitochondrially localized PKA reverses mitochondrial pathology and 11 dysfunction in a cellular model of Parkinson’s disease,” Cell Death and Diﬀerentiation, 2011. [86] V. S. Van Laar, B. Arnold, S. J. Cassady, C. T. Chu, E. A. Burton, and S. B. Berman, “Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization,” Human Molecular Genetics, vol. 20, no. 5, Article ID ddq531, pp. 927–940, 2011. [87] J. D. Rothstein, “Current hypotheses for the underlying biology of amyotrophic lateral sclerosis,” Annals of Neurology, vol. 65, no. 1, pp. S3–S9, 2009. [88] A. K. Aﬁﬁ, F. P. Aleu, J. Goodgold, and B. MacKay, “Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis,” Neurology, vol. 16, no. 5, pp. 475–481, 1966. [89] S. Sasaki and M. Iwata, “Dendritic synapses of anterior horn neurons in amyotrophic lateral sclerosis: an ultrastructural study,” Acta Neuropathologica, vol. 91, no. 3, pp. 278–283, 1996. [90] P. C. Wong, C. A. Pardo, D. R. Borchelt et al., “An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria,” Neuron, vol. 14, no. 6, pp. 1105–1116, 1995. [91] C. M. J. Higgins, C. Jung, and Z. Xu, “ALS-associated mutant SODIG93A causes mitochondrial vacuolation by expansion of the intermembrane space by involvement of SODI aggregation and peroxisomes,” BMC Neuroscience, vol. 4, article 16, 2003. [92] A. Raimondi, A. Mangolini, M. Rizzardini et al., “Cell culture models to investigate the selective vulnerability of motoneuronal mitochondria to familial ALS-linked G93ASOD1,” European Journal of Neuroscience, vol. 24, no. 2, pp. 387–399, 2006. [93] J. Magrane´, M. A. Sahawneh, S. Przedborski et al., “Mitochondrial dynamics and bioenergetics dysfuction is associated with synaptic alterations in mutant SOD motor neurons,” The Journal of Neuroscience, vol. 32, no. 1, pp. 229–242, 2012. [94] C. Delettre, G. Lenaers, J. M. Griﬀoin et al., “Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy,” Nature Genetics, vol. 26, no. 2, pp. 207–210, 2000. [95] M. Ferre´, D. Bonneau, D. Milea et al., “Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations,” Human Mutation, vol. 30, no. 7, pp. E692–E705, 2009. [96] V. I. Mayorov, A. J. Lowrey, V. Biousse, N. J. Newman, S. D. Cline, and M. D. Brown, “Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy,” BMC Biochemistry, vol. 9, no. 1, article 22, 2008. [97] M. Spinazzi, S. Cazzola, M. Bortolozzi et al., “A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function,” Human Molecular Genetics, vol. 17, no. 21, pp. 3291–3302, 2008. [98] A. Olichon, L. Baricault, N. Gas et al., “Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis,” The Journal of Biological Chemistry, vol. 278, no. 10, pp. 7743–7746, 2003. [99] S. Z u¨chner, I. V. Mersiyanova, M. Muglia et al., “Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot- Marie-Tooth neuropathy type 2A,” Nature Genetics, vol. 36, no. 5, pp. 449–451, 2004.